Real-Time Experience of Abrocitinib for the Treatment of Mucous Membrane Pemphigoid: A Case Report
Open Access
- 1 February 2024
- journal article
- case report
- Published by Taylor & Francis in Patient Preference and Adherence
- Vol. ume 18, 503-506
Abstract
Background: Mucous membrane pemphigoid (MMP), a rare autoimmune vesiculous and erosive disorder, may affect multiple mucous membranes, with the oral cavity being the most commonly affected site. Its treatment depends on the site(s) of mucosal involvement and disease severity. Patients and Methods: A 62-year-old female patient with MMP that predominantly involved the oral cavity strongly rejected systemic corticosteroid or immunosuppressive agents and was successfully treated with abrocitinib, a highly selective JAK-1 inhibitor with a good safety profile. Results: The case demonstrated good efficacy and safety profile of abrocitinib for the treatment of MMP with predominant oral involvement. Conclusion: Abrocitinib is a promising agent for the treatment of MMP with oral involvement.Keywords
This publication has 11 references indexed in Scilit:
- Abrocitinib‐A promising option for patients with refractory bullous pemphigoidJournal of the European Academy of Dermatology and Venereology, 2023
- Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published LiteratureMedicina, 2023
- Successful treatment of recalcitrant mucous membrane pemphigoid with multisystem involvement with baricitinib and methotrexateJAAD Case Reports, 2022
- Rapid improvement in pruritus in atopic dermatitis patients treated with upadacitinib: a real‐life experienceJournal of the European Academy of Dermatology and Venereology, 2022
- Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic DermatitisJAMA Dermatology, 2021
- Tofacitinib for refractory ocular mucous membrane pemphigoidAmerican Journal of Ophthalmology Case Reports, 2021
- Dupilumab as a novel therapy for bullous pemphigoid: A multicenter case seriesJournal of the American Academy of Dermatology, 2020
- JAK-inhibitors in dermatology: current evidence and future applicationsJournal of Dermatological Treatment, 2018
- Expression of the JAK/STAT Signaling Pathway in Bullous Pemphigoid and Dermatitis HerpetiformisMediators of Inflammation, 2017
- The First International Consensus on Mucous Membrane PemphigoidArchives of Dermatology, 2002